Invasive EEG monitoring is one of the best tools available for localization of epileptogenic foci in the brain. However, published data in mixed series of adult and pediatric patients show high incidence of epidural bacterial contamination, cerebrospinal fluid leakage, and skin infection after subdural electrode implantation. We sought to determine whether the complication rate from prolonged subdural electrode implantation would be lower in a purely pediatric series. Thirty-three subdural electrode implantation procedures were performed in 29 pediatric patients (age range 4–19) for an average of 7.2 days (range 3–14 days). Electrode number varied from 32 to >128 with a range of 4–11 electrode wires piercing the skin >1 cm from the primary incision. Of the 33 implantations and resections (66 craniotomies), 5 were for reimplantation. There were no permanent complications related to grid implantation. Transient complications included 1 case of prolonged prothrombin time and 1 patient with unexplained fever, both of which resolved upon removal of the grids. There were two culture-positive infections, one epidural and one superficial, both in patients undergoing reimplantation. There was no percutaneous cerebrospinal fluid leakage noted and no operation was aborted due to bleeding caused by grid placement. Our data suggest that subdural grid implantation in children is remarkably safe even for prolonged implantation, though infectious risk is significantly higher in reoperation (p = 0.019). This observation may contribute to lowering the threshold for two-stage invasive monitoring approaches in children with epilepsy.

Keywords:
Epileptogenic foci, Subdural grid implantation, Invasive electroencephalography monitoring
1.
Adelson PD, O’Rourke DK, Albright AL: Chronic invasive monitoring for identifying seizure foci in children. Neurosurg Clin N Am 1995;6:491–504.
2.
Dubeau F, McLachlan RS: Invasive electrographic recording techniques in temporal lobe epilepsy. Can J Neurol Sci 2000;27(suppl 1):S29–S34; discussion S50–S52.
3.
Jayakar P, Duchowny M, Resnick TJ: Subdural monitoring in the evaluation of children for epilepsy surgery. J Child Neurol 1994;9(suppl 2):61–66.
4.
Logar C, Walzl B, Lechner H: Role of long-term EEG monitoring in diagnosis and treatment of epilepsy. Eur Neurol 1994;34(suppl 1):29–32.
5.
Simon SL, Telfeian A, Duhaime AC: Complications of invasive monitoring used in intractable pediatric epilepsy. Pediatr Neurosurg 2003;38:47–52.
6.
Lee WS, Lee JK, Lee SA, Kang JK, Ko TS: Complications and results of subdural grid electrode implantation in epilepsy surgery. Surg Neurol 2000;54:346–351.
7.
Wiggins GC, Elisevich K, Smith BJ: Morbidity and infection in combined subdural grid and strip electrode investigation for intractable epilepsy. Epilepsy Res 1999;37:73–80.
8.
Behrens E, Schramm J, Zentner J, Konig R: Surgical and neurological complications in a series of 708 epilepsy surgery procedures. Neurosurgery 1997;41:1–9; discussion 9–10.
9.
Duport S, Stoppini L, Correges P: Electrophysiological approach of the antiepileptic effect of dexamethasone on hippocampal slice culture using a multirecording system: The Physiocard. Life Sci 1997;60:251–256.
10.
Arabi Y, Memish ZA, Balkhy HH, Francis C, Ferayan A, Al Shimemeri A, Almuneef MA: Ventriculostomy-associated infections: incidence and risk factors. Am J Infect Control 2005;33:137–143.
11.
Park P, Garton HJ, Kocan MJ, Thompson BG: Risk of infection with prolonged ventricular catheterization. Neurosurgery 2004;55:594–599; discussion 599–601.
© 2006 S. Karger AG, Basel
2006
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.